SCHEMBL6156891

SCHEMBL6156891

Cc1cc(NC(=O)NN(c2ccccc2)c2cccc(C(=N)NO)c2)ccc1N1CCCCC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 3/20 0.39
SMN1; SMN2 Q16637 5/20 0.38
TSHR P16473 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 7/20 0.37
MAPT P10636 4/20 0.37
POLB P06746 2/20 0.37
GFER P55789 2/20 0.35
GAA P10253 2/20 0.35
HPGD P15428 3/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.34
GLA P06280 1/20 0.34
PKM P14618 1/20 0.34
IDH2 P48735 1/20 0.34
CYP1A2 P05177 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6156656 0.92 F10 (0.47) F10SMN1; SMN2TSHRNPC1RAB9A
SCHEMBL6157189 0.84 KCNJ6 (0.40) SMN1; SMN2TSHRNPC1RAB9AKMT2A
SCHEMBL6156652 0.84 F10 (0.38) F10SMN1; SMN2TSHRNPC1RAB9A
SCHEMBL6156433 0.83 F10 (0.43) F10SMN1; SMN2TSHRNPC1RAB9A
SCHEMBL6158842 0.81 KMT2A (0.38) F10SMN1; SMN2TSHRNPC1RAB9A
SCHEMBL6156444 0.78 F10 (0.62) F10SMN1; SMN2TSHRNPC1RAB9A
SCHEMBL6159444 0.78 F10 (0.37) F10SMN1; SMN2TSHRNPC1RAB9A
SCHEMBL5163880 0.78 F10 (0.46) F10SMN1; SMN2TSHRNPC1RAB9A
SCHEMBL5164661 0.77 F10 (0.43) F10SMN1; SMN2TSHRNPC1RAB9A
SCHEMBL5164836 0.74 F10 (0.46) F10TSHRKMT2AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US claimed
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US disclosed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP disclosed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases SERPINC1, F11, F12 F10 6/4885SMN1; SMN2 3250/4885TSHR 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.